Jupipac 100 Injection contains Paclitaxel at a concentration of 6 mg/ml, a chemotherapeutic agent widely used in the treatment of various malignancies. Paclitaxel is a mitotic inhibitor that stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division and inducing apoptosis in rapidly proliferating cancer cells. Jupipac 100 is indicated for the treatment of ovarian cancer, breast cancer, non-small cell lung cancer, and Kaposi’s sarcoma, among other solid tumors. Administration of Jupipac 100 Injection should be performed intravenously under strict medical supervision, with dosing tailored to the specific cancer type and patient condition. Premedication with corticosteroids, antihistamines, and H2 antagonists is recommended to reduce hypersensitivity reactions commonly associated with Paclitaxel. Common adverse effects include neutropenia, peripheral neuropathy, alopecia, myalgia, and hypersensitivity reactions. Caution is advised in patients with preexisting neuropathy, hepatic impairment, or compromised bone marrow function. Jupipac 100 Injection is contraindicated in patients with severe hypersensitivity to Paclitaxel or its excipients. Due to its cytotoxic nature, appropriate handling and disposal procedures should be followed to minimize exposure risk. Regular monitoring of blood counts and liver function tests is essential during therapy to ensure patient safety and optimize therapeutic outcomes.